Advertisement

American Journal of Clinical Dermatology

, Volume 4, Issue 8, pp 573–581 | Cite as

The Social and Economic Burden of Venous Leg Ulcers

Focus on the Role of Micronized Purified Flavonoid Fraction Adjuvant Therapy
  • Marian Simka
  • Eugeniusz Majewski
Review Article

Abstract

Chronic venous insufficiency (CVI) occurs in a relatively large proportion of the population and is associated with significant morbidity, high cost of healthcare, loss of productivity and reduced quality of life. Lower extremity ulcers related to CVI have been estimated to affect 0.2–1% of the population in developed countries. The prevalence of venous ulcers in the US is estimated at 500 000–600 000, and increases with age. Estimates of the annual incidence of leg ulcer in the UK and Switzerland are 3.5 and 0.2 per 1000 individuals, respectively. Treatment of venous ulcers can be expensive, leading to a large economic burden on health services in many countries. The annual cost of CVI is estimated to be more than $US1 billion in the US and between £400–600 million in the UK. Current treatments for CVI include surgery, sclerotherapy, compressive therapy (conventional therapy) and adjuvant pharmacotherapy. Various pharmacological agents have been used as adjuvant therapy but in many cases there is no definitive evidence of their efficacy.

Effective treatment programs for venous leg ulcers could substantially reduce the economic impact of CVI on health services. In controlled studies, micronized purified flavonoid fraction (MPFF) adjuvant therapy has been shown to increase significantly the number of healed venous leg ulcers and to reduce significantly the healing time of ulcers compared with conventional therapy alone, potentially leading to an improvement in patients’ quality of life. The treatment of venous leg ulcers with MPFF was also found to reduce overall treatment costs compared with conventional therapy alone. In a retrospective cost-effectiveness analysis based on direct medical costs only, MPFF therapy improved the cost-effectiveness ratio by 45% compared with conventional therapy. If intangible costs, such as loss of quality of life were included, the difference in cost-effectiveness ratios is likely to be even greater in favor of MPFF. Sensitivity analyzes showed that even with a 20% increase in drug price the cost-effectiveness ratio for MPFF therapy was substantially better than that for conventional therapy ($US1061.8 vs 1871.9 per ulcer healed). Hence, the addition of MPFF adjuvant therapy to the treatment of venous leg ulcers would be effective and potentially cost saving.

Keywords

Conventional Therapy Ulcer Healing Systemic Adjuvant Therapy Venous Ulcer Chronic Venous Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This paper was supported by an educational grant from Servier.

References

  1. 1.
    Valencia IC, Fallabella A, Kirsner RS, et al. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol 2001; 44 (3): 401–21PubMedCrossRefGoogle Scholar
  2. 2.
    Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Int Angiol 1999; 18: 83–102PubMedGoogle Scholar
  3. 3.
    Ramelet AA. Clinical benefits of Daflon 500mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: 49–56CrossRefGoogle Scholar
  4. 4.
    De Castro Silva M. Chronic venous insufficiency of the lower limbs and its socio-economic significance. Int Angiol 1991; 10: 152–7Google Scholar
  5. 5.
    Phillips T, Stanton B, Provan A, et al. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994; 31: 49–53PubMedCrossRefGoogle Scholar
  6. 6.
    Franks PJ, Moffatt CJ. Health related quality of life in patients with venous ulceration: use of the Nottingham Health Profile. Qual Life Res 2001; 10: 693–700PubMedCrossRefGoogle Scholar
  7. 7.
    Marston WA, Carlin RE, Passman MA, et al. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg 1999; 30: 491–8PubMedCrossRefGoogle Scholar
  8. 8.
    Olin JW, Beusterien KM, Childs MB, et al. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med 1999; 4: 1–7PubMedGoogle Scholar
  9. 9.
    Cornwall JV, Doré CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986; 73: 693–6PubMedCrossRefGoogle Scholar
  10. 10.
    Douglas WS, Simpson NB. Guidelines for the management of chronic venous leg ulceration: report of a multidisciplinary workshop. British Association of Dermatologists and the Research Unit of the Royal College of Physicians. Br J Dermatol 1995; 132: 446–52PubMedCrossRefGoogle Scholar
  11. 11.
    Nelzen O, Bergqvist D, Lindhagen A, et al. Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. J Epidemiol Community Health 1991; 45: 184–7PubMedCrossRefGoogle Scholar
  12. 12.
    Skene AI, Smith JM, Dore CJ, et al. Venous leg ulcers: a prognostic index to predict time to healing. BMJ 1992; 305: 1119–21PubMedCrossRefGoogle Scholar
  13. 13.
    Callam MJ, Harper DR, Dale JJ, et al. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987; 294: 1389–91CrossRefGoogle Scholar
  14. 14.
    Lévy E, Los F, Chevalier H, et al. The 1999 Venous Disease Survey: epidemiology, management, and patient profiles. Angiology 2001; 52: 195–9PubMedGoogle Scholar
  15. 15.
    Jantet G, RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF Study. Angiology 2002; 53: 245–56CrossRefGoogle Scholar
  16. 16.
    Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement. Circulation 2000; 102: E126–63CrossRefGoogle Scholar
  17. 17.
    Laing W. Chronic venous disease of the leg. London: Office of Health Economics, 1992: 1–44Google Scholar
  18. 18.
    Lévy E, Lévy P. Management of venous leg ulcers by French physicians, diversity and related costs: a prospective and medicoeconomic observational study [in French]. J Mal Vasc 2001; 26: 39–44PubMedGoogle Scholar
  19. 19.
    Simka M. Application of various types of dressings and cost of management of venous ulceration. Abstract book of the 20th World Congress of the International Union of Angiology; 2002 Apr 7–11; New York City: 134Google Scholar
  20. 20.
    Bosanquet N, Franks P, Moffatt C, et al. Community leg ulcer clinics: cost-effectiveness. Health Trends 1993–1994; 25: 146–8PubMedGoogle Scholar
  21. 21.
    Faresjö T, Frödin T, Vahlquist C, et al. Costs of the treatment of leg ulcers: initiating a quality assurance process. Int J Health Care Qual Assur Inc Leadersh Health Serv 1997; 10: 125–30PubMedGoogle Scholar
  22. 22.
    Morrell CJ, Walters SJ, Dixon S, et al. Cost effectiveness of community leg ulcer clinics: randomised controlled trial. BMJ 1998; 316: 1487–91PubMedCrossRefGoogle Scholar
  23. 23.
    Pieper B, Szczepaniak K, Templin T. Psychosocial adjustment, coping, and quality of life in persons with venous ulcers and a history of intravenous drug use. J Wound Ostomy Continence Nurs 2000; 27: 227–37PubMedGoogle Scholar
  24. 24.
    Bosanquet N, Franks P. Venous disease: the new international challenge. Phlebology 1996; 11: 6–9Google Scholar
  25. 25.
    McInnes E, Cullum N, Nelson EA, et al. The development of a national guideline on the management of leg ulcers. J Clin Nurs 2000; 9: 208–17PubMedCrossRefGoogle Scholar
  26. 26.
    Cresswell J. New guidelines on venous leg ulcer management. Community Nurse 1999; 5: 53–5PubMedGoogle Scholar
  27. 27.
    Weingarten MS. State-of-the-art treatment of chronic venous disease. Clin Infect Dis 2001; 32: 949–54PubMedCrossRefGoogle Scholar
  28. 28.
    The Alexander House Group. Consensus paper on venous leg ulcers. Phlebology 1992; 7: 48–58Google Scholar
  29. 29.
    Coleridge Smith PD. The drug treatment of chronic venous insufficiency and venous ulceration. In: Gloviczki P, Yao JST, editors. Handbook of venous disorders. 2nd ed. Arnold, London: 2001 JulGoogle Scholar
  30. 30.
    Alguire PC, Mathes BM. Chronic venous insufficiency and venous ulceration. J Gen Intern Med 1997; 12: 374–83PubMedCrossRefGoogle Scholar
  31. 31.
    Paquette D, Falanga V. Leg ulcers. Clin Geriatr Med 2002; 18: 77–88PubMedCrossRefGoogle Scholar
  32. 32.
    Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604–6PubMedGoogle Scholar
  33. 33.
    Falabella AF, Carson P, Eaglstein WH, et al. The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. J Am Acad Dermatol 1998; 39: 737–40PubMedCrossRefGoogle Scholar
  34. 34.
    Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998; 134: 293–300PubMedCrossRefGoogle Scholar
  35. 35.
    Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001; 22: 365–72PubMedCrossRefGoogle Scholar
  36. 36.
    Bittiner SB. Oxpentifylline treatment of venous leg ulcers. BMJ 1990; 300: 1528PubMedCrossRefGoogle Scholar
  37. 37.
    Colgan MP, Dormandy JA, Jones PW, et al. Oxpentifylline treatment of venous ulcers of the leg. BMJ 1990; 300: 972–5PubMedCrossRefGoogle Scholar
  38. 38.
    Dale JJ, Ruckley CV, Harper DR, et al. Randomised, double-blind, placebo-controlled trial of pentoxifylline in the treatment of venous leg ulcers. 1999; 319: 875–8Google Scholar
  39. 39.
    Gajraj H, Jopp-McKay A, Stacey MC. Oxpentifylline treatment of venous leg ulcers [letter]. BMJ 1990; 300: 1725PubMedCrossRefGoogle Scholar
  40. 40.
    De Sanctis MT, Belcaro G, Cesarone MR, et al. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial: microcirculation and healing. Angiology 2002; 53 Suppl. 1: 49–51CrossRefGoogle Scholar
  41. 41.
    Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7: 208–13PubMedCrossRefGoogle Scholar
  42. 42.
    Jull AB, Waters J, Arroll B. Pentoxifylline for treating venous leg ulcers. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002: CD001733Google Scholar
  43. 43.
    Struckmann JR. Clinical efficacy of micronised purified flavonoid fraction: an overview. J Vasc Res 1999; 36 Suppl. 1: 37–41PubMedCrossRefGoogle Scholar
  44. 44.
    Guilhou J-J, Dereure O, Marzin L, et al. Efficacy of Daflon 500mg in venous leg ulcer healing: a double-blind, randomised, controlled versus placebo trial in 107 patients. Angiology 1997; 48: 77–85PubMedCrossRefGoogle Scholar
  45. 45.
    Gliński W, Chodynicka B, Roszkiewicz J, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology 1999; 14: 151–7CrossRefGoogle Scholar
  46. 46.
    Ibegbuna V, Nicolaides AN, Sowade O, et al. Venous elasticity after treatment with Daflon 500mg. Angiology 1997; 48: 45–9PubMedCrossRefGoogle Scholar
  47. 47.
    Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500mg. Angiology 2001; 52 Suppl. 1: 43–7CrossRefGoogle Scholar
  48. 48.
    Labrid C. Pharmacologic properties of Daflon 500mg. Angiology 1994; 45: 524–30PubMedGoogle Scholar
  49. 49.
    Garner RC, Garner JV, Gregory S, et al. Comparison of the absorption of micronized (Daflon 500mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci 2002; 91: 32–40PubMedCrossRefGoogle Scholar
  50. 50.
    Roztočil K, Štvrtinová V, Strejček J. Efficacy of a 6-month treatment with Daflon 500mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22: 24–31PubMedGoogle Scholar
  51. 51.
    Splawiński J. Cost-effectiveness analysis of micronized purified flavonoid fraction (MPFF) in the treatment of venous ulceration. Medicographia 2000; 22: 157–61Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Out-Patient Department of AngiologyPszczynaPoland
  2. 2.Department of General and Vascular SurgerySilesian Medical AcademyTychyPoland

Personalised recommendations